Pancreatic Cancer: Promises and Failures of Target Therapies

被引：7

作者：

Aroldi, Francesca ^{[1
]}

Bertocchi, Paola ^{[1
]}

Rosso, Edoardo ^{[2
]}

Prochilo, Tiziana ^{[1
]}

Zaniboni, Alberto ^{[1
]}

机构：

[1] Fdn Poliambulanza, UO Oncol Med, Brescia, Italy

[2] Fdn Poliambulanza, Dept Surg, Brescia, Italy

来源：

REVIEWS ON RECENT CLINICAL TRIALS | 2016年 / 11卷 / 01期

关键词：

Angiogenesis; hedgehog-; JAK-STAT; -notch; immunotherapy; pancreatic cancer; stroma; target therapies;

D O I：

10.2174/1574887110666150930122720

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Currently, few efficient therapies are available to battle pancreatic cancer. Mechanisms underlying this cancer are not well known and researchers are trying to identify new therapeutic targets. Here, we present a review of new treatments and their results in recent years.

引用

页码：33 / 38

页数：6

共 54 条

[1]

AIRTUM Working group, 2013, NUM CANCR IT 2013, P93

[2] Desmoplastic reaction in pancreatic cancer - Role of pancreatic stellate cells [J].

Apte, MV ;

Park, S ;

Phillips, PA ;

Santucci, N ;

Goldstein, D ;

Kumar, RK ;

Ramm, GA ;

Buchler, M ;

Friess, H ;

McCarroll, JA ;

Keogh, G ;

Merrett, N ;

Pirola, R ;

Wilson, JS .

PANCREAS, 2004, 29 (03) :179-187

[3] A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma [J].

Beatty, Gregory L. ;

Torigian, Drew A. ;

Chiorean, E. Gabriela ;

Saboury, Babak ;

Brothers, Alex ;

Alavi, Abass ;

Troxel, Andrea B. ;

Sun, Weijing ;

Teitelbaum, Ursina R. ;

Vonderheide, Robert H. ;

O'Dwyer, Peter J. .

CLINICAL CANCER RESEARCH, 2013, 19 (22) :6286-6295

[4] CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans [J].

Beatty, Gregory L. ;

Chiorean, Elena G. ;

Fishman, Matthew P. ;

Saboury, Babak ;

Teitelbaum, Ursina R. ;

Sun, Weijing ;

Huhn, Richard D. ;

Song, Wenru ;

Li, Dongguang ;

Sharp, Leslie L. ;

Torigian, Drew A. ;

O'Dwyer, Peter J. ;

Vonderheide, Robert H. .

SCIENCE, 2011, 331 (6024) :1612-1616

[5] A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer [J].

Bergmann, L. ;

Maute, L. ;

Heil, G. ;

Ruessel, J. ;

Weidmann, E. ;

Koeberle, D. ;

Fuxius, S. ;

Weigang-Koehler, K. ;

Aulitzky, W. E. ;

Woermann, B. ;

Hartung, G. ;

Moritz, B. ;

Edler, L. ;

Burkholder, I. ;

Scheulen, M. E. ;

Richly, H. .

EUROPEAN JOURNAL OF CANCER, 2015, 51 (01) :27-36

[6] Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297 [J].

Berlin, JD ;

Catalano, P ;

Thomas, JP ;

Kugler, JW ;

Haller, DG ;

Benson, AB .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (15) :3270-3275

[7] A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy [J].

Bodoky, Gyoergy ;

Timcheva, Constanta ;

Spigel, David Robert ;

La Stella, Phillip Joseph ;

Ciuleanu, Tudor Eliade ;

Pover, G. ;

Tebbutt, N. C. .

INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) :1216-1223

[8]

Borad MJ, 2012, J CLIN ONCOL, V30, P77

[9] Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].

Burris, HA ;

Moore, MJ ;

Andersen, J ;

Green, MR ;

Rothenberg, ML ;

Madiano, MR ;

Cripps, MC ;

Portenoy, RK ;

Storniolo, AM ;

Tarassoff, P ;

Nelson, R ;

Dorr, FA ;

Stephens, CD ;

VanHoff, DD .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413

[10]

CALDAS C, 1995, INT J PANCREATOL, V18, P1

← 1 2 3 4 5 6 →